29 Jan 2016

Maintaining the rhythm

- Christian Glennie
- 2 pages

A strategic partnership with AliveCor and US (FDA 510k) and EU (CE mark) approvals for the mobile cardiac telemetry (MCT) patch kicks off an important year for LifeWatch. With a full turnaround of the company’s fortunes nearly complete, there is a renewed focus on growth via organic and external means. The recent purchase of FlexLife Health and suspension of its home sleep testing services are testament to LifeWatch’s new strategic direction.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Maintaining the rhythm

LifeWatch (LIFE:SWX) | 0 0 0.0%

Published: 29 Jan 2016
Author: Christian Glennie
Pages: 2

A strategic partnership with AliveCor and US (FDA 510k) and EU (CE mark) approvals for the mobile cardiac telemetry (MCT) patch kicks off an important year for LifeWatch. With a full turnaround of the company’s fortunes nearly complete, there is a renewed focus on growth via organic and external means. The recent purchase of FlexLife Health and suspension of its home sleep testing services are testament to LifeWatch’s new strategic direction.